Advertisement

FortuneIndia

Quick Links :

Fortune 500 India
40 Under 40
Most Powerful Women
Budget 2024
India's Richest
The Next 500
Best B-Schools
Opinion
First Edit
Multimedia
Events

Fortune 500 India
40 Under 40
Most Powerful Women
The Next 500
Best B-Schools
All Rankings
Events
Macro
Enterprise
Technology
Reviews
Venture
Investing
Multimedia
Fortune India Exchange
Bystander
Opinion
Infographics
Ideas
Long Reads
People
Buy on Amazon
Polemicist
Annual Subscription

difizma

Share

January 2023

Lupin launches asthma drug DIFIZMA; stock gains

Lupin launches asthma drug DIFIZMA; stock gains

The pharma major has launched a novel fixed-dose triple drug combination ‘DIFIZMA’ to treat inadequately controlled asthma.

By fortuneindia.com

Advertisement

Top Stories

IndiGo Q1 profit falls 11.7% to ₹2,728 crore

IndiGo Q1 profit falls 11.7% to ₹2,728 crore

Ashok Leyland shares surge 7% as UBS recommends 'buy'

Ashok Leyland shares surge 7% as UBS recommends 'buy'

Paytm shares soar 10% on FDI clearance

Paytm shares soar 10% on FDI clearance

Income tax tribunal quashes ₹2,337 cr tax demand against Hero MotoCorp

Income tax tribunal quashes ₹2,337 cr tax demand against Hero MotoCorp

Tech Mahindra shares plunge 6.67% post Q1 results

Tech Mahindra shares plunge 6.67% post Q1 results

Advertisement

Advertisement

Top Stories

IndiGo Q1 profit falls 11.7% to ₹2,728 crore

IndiGo Q1 profit falls 11.7% to ₹2,728 crore

Ashok Leyland shares surge 7% as UBS recommends 'buy'

Ashok Leyland shares surge 7% as UBS recommends 'buy'

Paytm shares soar 10% on FDI clearance

Paytm shares soar 10% on FDI clearance

Income tax tribunal quashes ₹2,337 cr tax demand against Hero MotoCorp

Income tax tribunal quashes ₹2,337 cr tax demand against Hero MotoCorp

Tech Mahindra shares plunge 6.67% post Q1 results

Tech Mahindra shares plunge 6.67% post Q1 results

Contact Us
Vision & Core Values
Terms of Use
Privacy & Cookie Policy

Powered by Quintype